Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC

Rheumatology (Oxford). 2022 Dec 23;62(1):e1-e3. doi: 10.1093/rheumatology/keac388.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adalimumab / therapeutic use
  • Antirheumatic Agents* / therapeutic use
  • Arthritis, Psoriatic* / drug therapy
  • Heterocyclic Compounds, 3-Ring / therapeutic use
  • Humans
  • Treatment Outcome

Substances

  • upadacitinib
  • Antirheumatic Agents
  • Adalimumab
  • Heterocyclic Compounds, 3-Ring